Becton, Dickinson and Co $ 59.24 0 (0%)
Becton, Dickinson and Co News and Headlines -
This report is about Becton, Dickinson and Co. (BDX) and covers the company's fiscal year ended Sept. 30, 2020. Listed earnings and metrics utilizing earnings are for that specific 12-month time period unless otherwise noted. Unaudited or reviewed financial information is not apart of, nor included in, this report.
What they do
Becton, Dickinson and Co., commonly known as BD, is a medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by health care institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry
The health care sector is considered a defensive sector as people will seek out treatment for illness and aliments regardless of the status of the economy. Many companies in this sector literally provide products that consumers cannot live without. This allows for earnings and revenue growth to be more consistent even in a recession.
Many of these companies are able to pay and raise their dividends for long periods of time.
One of my favorite names in the health care sector is Becton, Dickinson & Co. (BDX). We will examine the company's historical performance, dividend history, recession performance, debt and
When it comes to Covid-19, Becton, Dickinson and Co. (BDX) hasn't gained the attention of vaccine developers like Pfizer Inc. (PFE) and Johnson & Johnson (JNJ), nor those companies with treatments like Gilead Sciences Inc. (GILD). But the New Jersey-based medical device company has hardly been sitting on the sidelines.
BD, as it is also known, expects to capture about $1.5 billion in sales from its Covid diagnostic test in 2021, most of it coming in the first half of the year, CEO Thomas Polen told analysts in a conference call on Nov. 5 following the release of fourth-quarter and
Generation Investment Management, the firm founded by Al Gore (Trades, Portfolio) and David Blood, disclosed this week that its top five trades for the third quarter included a new position in Cisco Systems Inc. (CSCO), position boosts in Analog Devices Inc. (ADI) and Becton, Dickinson & Co. (BDX) and position reductions in Alphabet Inc. (GOOG) and Varian Medical Systems Inc. (VAR).
Gore, a former Vice President of the United States, co-founded the London-based firm in 2004. The firm focuses on a long-term investment perspective, focusing on sustainability within markets with companies that strategically manage environmental, social and
PerkinElmer Inc. (PKI) tops the list of molecular diagnostic tests for Covid-19 based on its ability to detect the smallest amount of virus, according to a report from the Food and Drug Administration.
The FDA listed each diagnostic's limit of detection, a number describing the lowest amount of virus particles in a sample that could still provide a correct test result, reported FierceBiotech. The samples are measured in the number of individual units of RNA detectable by nucleic acid amplification, per milliliter. The lower the number, the better.
PerkinElmer's coronavirus detection kit scored 180. Its nearest competitors—by about
Managed by a nine-person team, the New York-based fund invests in high-quality companies from around the world in order to achieve long-term capital appreciation. It looks for companies that have resilient business franchises and growth potential.
With these criteria in mind, the fund entered one new position during the quarter, reduced 13 holdings and added to 17 other investments. Its most notable trades for the quarter included establishing a holding in Roper Technologies Inc.
Generation Asset Management, the firm founded by David Blood and Al Gore (Trades, Portfolio), disclosed this month that its top five trades in the second quarter included increased bets in Becton, Dickinson and Co. (BDX), Palo Alto Networks Inc. (PANW) and Varian Medical Systems Inc. (VAR), and position reductions in Charles Schwab Corp. (SCHW) and MercadoLibre Inc. (MELI).
The former Vice President of the United States co-founded the London-based firm in 2004, seeking long-term capital appreciation through fundamental analysis and bottom-up stock picking. Generation focuses on sustainability within markets with companies that strategically manage their economic, social
The T Rowe Price Equity Income Fund (Trades, Portfolio), part of Baltimore-based T. Rowe Price Group Inc. (TROW), disclosed this week that its top five buys during the second quarter included new positions in Volkswagen AG (XTER:VOW3) and Merck & Co. Inc. (MRK). The fund also raised its stakes in Enbridge Inc. (ENB), Becton, Dickinson and Co. (BDX) and Loews Corp. (L).
Fund manager John Linehan pursues dividend income and long-term growth potential. The Equity Income Fund invests in the stocks of established companies that are expected to pay above-average dividends and are trading at attractive valuations.
Al Gore (Trades, Portfolio), co-founder of Generation Investment Management, has released his portfolio for the first quarter of 2020. Gore sold out of his holding in Credicorp Ltd. (BAP), bought into Palo Alto Networks Inc. (PANW), Gartner Inc. (IT) and Trimble Inc. (TRMB), and added to his existing holding of Becton, Dickinson and Co. (BDX).
Generation is an investment management company based out of London that is dedicated to “long-term investing, integrated sustainability research, and client alignment.” The company was founded in 2004 by Gore and David Blood. The firm focuses on a long-term investment perspective, focusing
Denmark-based Coloplast (OCSE:COLO B) develops, manufactures and markets medical devices and services to “make life easier for people for intimate healthcare needs.”
The company is a global leader in its niches, with a leading position in ostomy care (for people who live with a stoma) and continence care (for bladder or bowel management). These two product lines constitute the Chronic Care segment at Coloplast, which accounted for more than three-quarters of total sales as of fiscal 2018 and 2019. The company is also a major player in wound care for difficult-to-heal wounds and interventional urology for dysfunctional urinary and reproductive
Hillman Capital Management recently disclosed its portfolio updates for the reported first quarter of 2020, which ended on March 31.
Mark Hillman (Trades, Portfolio) is the president, CEO and chief investment officer of the firm, which he founded in 1998. The firm’s strategy is to invest in companies with distinct competitive advantages that have fallen temporarily out of favor with investors due to short-term, non-recurring issues. Hillman considers factors such as cash flow, dividends, sales, earnings, book value and projected growth rates when valuing a business.
As of the quarter’s end, the fund held shares of 36
The fund was started in 1985. Brian Rogers managed the portfolio for its first 30 years, establishing a conservative, value-oriented investing strategy to pursue dividend income and long-term capital growth. The strategy prefers large-cap stocks that return consistent, higher-than-average dividend income, are out of favor with the market and are expected to grow their earnings significantly. In October of 2015, John Linehan succeeded Rogers as the fund’s portfolio manager.
As of the
The S&P 500 index saw its total sales grow at an annualized 4% rate over the past five years through Sept. 30, 2019. On the tailwind of this, the value of the benchmark for the U.S. market rose by nearly 45%.
The following companies have outperformed the benchmark over the past five years in this regard. As a result of higher growth per year, their stocks posted share price returns in the range of 35% to 120%.
The past is no guarantee of future performance, but no one can deny that stocks growing their sales faster than the market are
Based in New York, the fund is managed by a nine-person team that invests based on a bottom-up stock selection process. The team looks for companies that have strong franchises, high and sustainable return on invested capital, strong free cash flow, difficult-to-duplicate intangible assets, good financial strength and capable management.
Based on the above investing criteria, the firm added the most to its holdings in Thermo Fisher Scientific Inc. (TMO), Philip Morris
Utah-based Utah Medical Products (UTMD) develops, manufactures and markets a broad spectrum of disposable and reusable specialty medical devices, primarily focusing on products for women and newborns.
With a total staff of less than 200, the $350 million market-cap business has a global presence in more than 100 countries. As of fiscal 2018, the domestic and international markets each accounted for nearly half of the company’s total sales. Per the latest filings, individual insiders own, in aggregate, almost 7% of the company, which is a positive sign of the alignment of interests between the management and shareholders.
One thing that
Crane Co (CR), Simmons First National Corporation (SFNC) and Becton, Dickinson, and Company (BDX) announced dividends after the closing bell on Monday, Jan. 28. These fast-growing dividend stocks have also been paying dividends for about three decades.
Shares of Crane Co were up 5.11% to a price of $87.85 per share in after-hours trading on Monday after the company announced a 10.3% rise in the quarterly cash dividend to 43 cents per common share, up from the previous dividend of 39 cents.
Crane will pay its shareholders on March 11. In order to benefit, investors must be on the
Texas-based Atrion Corporation (ATRI) engages in developing and manufacturing products for niche markets, mainly in the health care and medical industry.
Despite being a small-cap stock (approximately $1.34 billion market cap as of Jan. 28th, 2020), the business owns a diversified portfolio of market-leading products in the respective niches, including soft contact lens disinfection cases, clamps for IV sets, cardiac surgery vacuum relief valves, minimally invasive surgical tapes and valves and inflation devices used in marine and aviation safety products. Notably, the company’s proprietary technology, MPS2 Myocardial Protection System, is the only system used in open-heart surgery that delivers to
When Kevin Conroy was recruited for the top job at Exact Sciences Corp. (EXAS), he knew it would require a leap of faith to take on the role. After all, the Madison, Wisconsin-based cancer diagnostics company had an unenviable track record and an uncertain future.
Exact had been unsuccessful twice in developing colorectal cancer screening tests, was quickly depleting its cash and had a pipeline that didn’t inspire a great deal of confidence. These issues were reflected in the company’s share price of about $2.65. That was even lower than its initial public offering price in 2001.
My, how things
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.
Celgene Corp. (CELG) is held by 20 gurus
The company, which develops therapeutics for the treatment of immunological diseases, has a market cap of $69.76 billion. Its revenue of $15.76 billion has grown 23.40% over a 10-year period.
The stock is trading with a price-earnings ratio of 14.16. The share price of $93 is 1% below the 52-week high and 66.82% above the 52-week low. Over the last 10 years, it has returned 283%.
The company’s largest shareholder among the gurus is David
With rapid growth projected for the market for wearable drug delivery devices, investors would be wise to consider some of the key players in the business.
Two standouts are Boston-area-based Insulet (PODD) and West Pharmaceutical Services (WST), which is headquartered in Exton, Pennsylvania. These companies don’t make the drugs. They develop the devices patients wear that deliver the medications.
Both firms have rewarded shareholders handsomely. Insulet, which is worth more than $6 billion, trades at more than $103. That’s up more than 150% during the past five years. West has been even more generous to its faithful. Shares
|2020-04-23 $ 62.64 (-0.59%)|
|2020-02-10 $ 60.21 (2.12%)|